Stifel Financial Corp Sells 9,185 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL)

Stifel Financial Corp cut its position in Precision BioSciences, Inc. (NASDAQ:DTIL) by 30.2% in the 3rd quarter, Holdings Channel.com reports. The firm owned 21,270 shares of the company’s stock after selling 9,185 shares during the period. Stifel Financial Corp’s holdings in Precision BioSciences were worth $191,000 at the end of the most recent quarter.

Separately, Janus Henderson Group PLC increased its stake in shares of Precision BioSciences by 10.9% in the third quarter. Janus Henderson Group PLC now owns 702,069 shares of the company’s stock valued at $6,322,000 after buying an additional 68,943 shares during the period. 37.99% of the stock is currently owned by institutional investors.

Precision BioSciences Trading Down 8.4 %

DTIL opened at $4.26 on Tuesday. Precision BioSciences, Inc. has a fifty-two week low of $4.13 and a fifty-two week high of $19.43. The company has a debt-to-equity ratio of 0.34, a current ratio of 9.22 and a quick ratio of 9.22. The firm has a market capitalization of $32.68 million, a price-to-earnings ratio of 71.01 and a beta of 1.41. The company’s 50 day moving average price is $6.79 and its two-hundred day moving average price is $8.60.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.